Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2020-01-14 Regulatory Filings
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed under National Instrument 51-102, which is a regulatory filing requirement in Canada for disclosing material changes. The content describes a specific material change involving conversion of notes payable into common shares, including details about the transaction and regulatory exemptions. The document is short (2297 characters) and is a formal notification of a material change rather than a full financial report or earnings release. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-01-14 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, distribution dates, types of securities distributed, and purchaser information. This form is a regulatory filing used in Canada to report exempt distributions of securities. It is not an annual report, earnings release, or any other financial report but a specific regulatory disclosure related to securities distribution. The document is lengthy (15,000 characters) and contains substantive data about the distribution, not just an announcement or certification. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory documents that do not fit other specific categories.
2020-01-14 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the conversion of notes payable into common shares. It details the amounts converted, the issuance of shares, and related approvals. There is no detailed financial report, audit, or comprehensive financial data. The content focuses on a capital structure change through conversion of debt to equity, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report publication, nor a certification or regulatory filing. Therefore, the best classification is CAP with high confidence.
2020-01-14 English
Material change report - English.pdf
Regulatory Filings
2019-12-30 English
News release - English.pdf
Regulatory Filings
2019-12-19 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2019-09-27 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.